<DOC>
	<DOC>NCT02171962</DOC>
	<brief_summary>The objective of this study is to evaluate the Zilver® PTX® Drug-Eluting Peripheral Stent for treatment of lesions of the above-the-knee femoropopliteal artery in a Chinese patient population.</brief_summary>
	<brief_title>Zilver® PTX® in China</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>Symptoms of peripheral arterial disease corresponding to Rutherford Classification 24 Stenotic (&gt;50% diameter stenosis) or occluded lesion of the abovethe knee femoropopliteal artery Reference vessel diameter of 49 mm Lesion length up to 140 mm Unsuccessful arterial interventional treatment of the legs within 30 days prior to the study procedure Previous stent in the study vessel Bypass graft with an anastomosis in the study vessel Significant stenosis or occlusion of inflow tract not successfully treated prior to treating the study lesion No patent vessel of runoff</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Zilver® PTX® Drug-Eluting Peripheral Stent</keyword>
	<keyword>Above-the-Knee Femoropopliteal Artery</keyword>
	<keyword>Chinese patient</keyword>
</DOC>